Lys97

Site Information
tDDkTLPkLERKRLQ SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 466727

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:	leukemia ( 2 ) , chronic myelogenous leukemia ( 2 ) , liver cancer ( 4 ) , hepatocellular carcinoma ( 4 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 3 ) , HepG2 (hepatic) ( 4 ) , Jurkat (T lymphocyte) ( 1 ) , K562 (erythroid) ( 2 )

References
1	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
2	Moritz A (2010) CST Curation Set: 9820; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
3	Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40 19608861 Curated Info
4	Mitchell J (2005) CST Curation Set: 867; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info